How is the Corneal Endothelial Dystrophy Market Poised for Growth: Trends and Opportunities Through 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the corneal endothelial dystrophy market size evolved in recent years?
The market for corneal endothelial dystrophy has seen robust growth in recent times. It is expected to increase from $170.96 billion in 2024 to $185.38 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.4%. The expansion during the historical period is credited to factors such as growing healthcare spending, an increase in incidence of endothelial corneal dystrophy, an aging population, a rise in eye diseases, and a burgeoning prevalence of corneal disorders.
What are the predictions for the corneal endothelial dystrophy market size in the coming years?
Expectations point towards robust enlargement of the corneal endothelial dystrophy market in the subsequent years. The anticipated escalation in size is at a compound annual growth rate (CAGR) of 8.1%, reaching $252.88 billion by 2029. Elements contributing to this progress during the projected duration include escalating instances of corneal blindness in developing economies, heightened cognizance about eye health, growing demand for corneal transplants, and improved healthcare facilities, along with an augmented prevalence of chronic ailments. Notable trends during the forecast period incorporate development in regenerative care therapies, enhancement in medical technology, progress in diagnostic methods, technological improvements in the field of ophthalmic lasers, and other advanced innovations.
Get your corneal endothelial dystrophy market report here!
https://www.thebusinessresearchcompany.com/report/corneal-endothelial-dystrophy-global-market-report
What key factors are fueling the growth of the corneal endothelial dystrophy market?
An upsurge in the requirement for corneal transplants is believed to be the primary catalyst for the corneal endothelial dystrophy market’s expansion in the future. Corneal transplant surgery involves the replacement of an impaired or unhealthy cornea with a healthy donated one to enhance vision and overall ocular health. This growing need for corneal transplants is attributable to the increasing occurrence of corneal ailments, advancements in surgical procedures, and better organ donation rates. When treating corneal endothelial dystrophy, a healthy donor’s tissue replaces the impaired endothelium through corneal transplantation. This process clarifies the cornea, lessens edema, and enhances sight. For example, the US-based Eye Bank Association of America reported a 2.7% increase in domestic keratoplasty (a kind of corneal transplant operation) procedures in 2023, rising from 49,597 in 2022 to 50,925. As a result, the corneal endothelial dystrophy market is expanding due to the escalating demand for corneal transplants.
How is the global corneal endothelial dystrophy market divided into key segments?
The corneal endothelial dystrophy market covered in this report is segmented –
1) By Treatment: Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps
2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1, Congenital Hereditary Endothelial Dystrophy 2, Posterior Polymorphous Corneal Dystrophy, Fuchs Endothelial Corneal Dystrophy
3) By Diagnosis: Cornea Examination And Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count
4) By End-User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Phototherapeutic Keratectomy: Excimer Laser Therapy, Corneal Reshaping
2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant, Cryopreserved Amniotic Membrane Transplant
3) By Anterior Stromal Puncture: Manual Technique, Laser-Assisted Technique
4) By Conjunctival Flaps: Partial Flap Technique, Full Flap Technique
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21158&type=smp
Who are the key firms paving the way for growth in the corneal endothelial dystrophy market?
Major companies operating in the corneal endothelial dystrophy market are F. Hoffmann-La Roche AG, Abbvie (Allergan plc), Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, Emmecell S.R.L
What key trends are currently impacting the corneal endothelial dystrophy market’s development?
Major firms in the corneal endothelial dystrophy market are centering their efforts on crafting groundbreaking treatments such as allogeneic cell therapy. This approach seeks to address the gap in medical solutions through offering new, minimally invasive treatment alternatives that enhance patient results. The term allogeneic cell therapy describes the use of cells from a genetically different donor of the same species to treat a recipient. For example, Aurion Biotech Inc., a U.S. clinical-stage biotechnology corporation, introduced Vyznova (neltependocel) in Japan in September 2024 as a treatment for bullous keratopathy, a type of corneal endothelial illness. Aurion Biotech developed Vyznova (neltependocel) – a cell therapy designed to treat bullous keratopathy that causes corneal endothelial cell damage and visual impairment. It holds the distinction of being the initial approved cell therapy for corneal endothelial illness and has received approval in Japan. Vyznova involves the use of lab-grown corneal endothelial cells, enabling the creation of up to 1,000 doses from a single donor. This revolutionary treatment provides a less invasive option compared to corneal transplants, addressing the crippling scarcity of cornea donors and presenting a novel approach to restoring vision for corneal disease patients.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21158
What regions are contributing significantly to the growth of the corneal endothelial dystrophy market?
North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Anticholinergic Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report
Critical Care Antiarrhythmic Drugs Global Market Report 2025
Global Breast Cancer Monoclonal Antibodies Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
